Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs AARD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AARD Captures Overall Composite Edge (45.9 HOLD vs 58.1 HOLD), While EKSO Leads 3–2 on Growth & Valuation Pillars

AARD Overall Winner 6-Pillar Tally: EKSO 3 – 2 AARD (1 Tie) Matrix Metrics: EKSO 4 – 4 AARD

As of Nov 20, 2026, Aardvark Therapeutics, Inc. (AARD) captures the overall head-to-head institutional edge over Ekso Bionics Holdings, Inc. (EKSO) on higher Unified Composite conviction (45.9/100 HOLD vs. 58.1/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while EKSO wins 3–2 across the 6-pillar growth and valuation breakdown. EKSO trades at $11.80 (N/M Forward P/E, -119.7% operating margin) versus AARD at $0.92 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. AARD 45.9/100 HOLD), AARD captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -119.7% operating margin) and revenue trajectory (+0.0% vs. -38.3% YoY).
  • Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs AARD
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
AARD NASDAQ Head-to-Head Winner
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.92
-7.74% 1D
Market Cap $21.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.84β · 284% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.6%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.25 · SMA50: $3.35

6-Pillar Scorecard Institutional Category Breakdown (EKSO 3 – 2 AARD)

Columns: Metric · EKSO · AARD
1. Valuation Multiples EKSO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x N/M
2. Growth & Scale EKSO
Revenue Growth (YoY) -38.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M N/A
Market Cap $42.0M $21.9M
3. Profitability & Quality AARD
Gross Margin 53.5% N/A
Operating Margin -119.7% 0.0%
Net Profit Margin -91.4% 0.0%
Return on Equity (ROE) -107.6% -66.0%
4. Balance Sheet & Cash Flow EKSO
Cash Generation (TTM) -$11M EBITDA N/A
Cash Flow Margin -86.0% EBITDA Mgn N/A
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $73M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 147.3% (26th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (4) vs AARD (4)
Institutional Metric EKSO AARD Criterion Row Edge
Market Capitalization
Scale
$42.0M $21.9M Larger Scale EKSO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% +0.0% Higher Growth AARD
Operating Margin (TTM)
Profitability
-119.7% 0.0% Higher Margin AARD
Net Profit Margin
Profitability
-91.4% 0.0% Higher Margin AARD
Return on Equity (ROE)
Capital Efficiency
-107.6% -66.0% Higher ROE AARD
52-Week Range Position
Momentum
87% ($0–$14) 0% ($1–$17) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 3.84β · 284% Vol Lower Realized Risk EKSO
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) N/A ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +2.97 pp
EKSO: +25.53% · AARD: +22.56%
3M Horizon EKSO +86.31 pp
EKSO: +25.93% · AARD: -60.38%
6M Horizon EKSO +242.42 pp
EKSO: +192.8% · AARD: -49.62%
1Y Horizon EKSO +242.42 pp
EKSO: +192.8% · AARD: -49.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs AARD. Trailing 12-month operating profitability (EKSO -119.7% vs AARD 0.0%) and valuation multiples (EKSO N/M vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $21.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs AARD Key Questions & Quantitative Answers

As of Nov 20, 2026, Aardvark Therapeutics, Inc. (AARD) captures the overall head-to-head institutional edge over Ekso Bionics Holdings, Inc. (EKSO) on higher Unified Composite conviction (45.9/100 HOLD vs. 58.1/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while EKSO wins 3–2 across the 6-pillar growth and valuation breakdown. EKSO trades at $11.80 (N/M Forward P/E, -119.7% operating margin) versus AARD at $0.92 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. AARD 45.9/100 HOLD), AARD captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -119.7% operating margin) and revenue trajectory (+0.0% vs. -38.3% YoY). Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EKSO leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.

EKSO screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus AARD (-66.0% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.84β · 284% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.